{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:13:21Z","timestamp":1789514001021,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13311-023-01446-5","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T10:02:26Z","timestamp":1698314546000},"page":"1707-1722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-3254","authenticated-orcid":false,"given":"Sean A.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lemarchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifanie","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Outteryck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labalette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rogeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-023-01446-5_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib2","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"13","author":"Hauser","year":"2008","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1007\/s13311-023-01446-5_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1007\/s13311-023-01446-5_bib4","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01446-5_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01446-5_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01446-5_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1007\/s13311-023-01446-5_bib8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-023-01446-5_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa617","article-title":"Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience","author":"Evangelatos","year":"2021","journal-title":"Rheumatology"},{"key":"10.1007\/s13311-023-01446-5_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","author":"Maarouf","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B cell depletion therapy in MS according to memory B cell monitoring","author":"Novi","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing\u2013remitting multiple sclerosis","author":"Boremalm","year":"2021","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib13","doi-asserted-by":"crossref","first-page":"676686","DOI":"10.3389\/fimmu.2021.676686","article-title":"Memory B cells in multiple sclerosis: emerging players in disease pathogenesis","volume":"12","author":"DiSano","year":"2021","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-023-01446-5_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","author":"Rolfes","year":"2021","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10.1007\/s13311-023-01446-5_bib15","doi-asserted-by":"crossref","first-page":"e200056","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"12","key":"10.1007\/s13311-023-01446-5_bib16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab: a multicentric Italian-Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-023-01446-5_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01446-5_bib18","first-page":"938","article-title":"Memory B Cells predict relapse in rituximab-treated myasthenia gravis","volume":"18","author":"Ruetsch-Chelli","year":"2021","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1007\/s13311-023-01446-5_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-023-01446-5_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with Ocrelizumab: a retrospective cohort study","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-023-01446-5_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","author":"Smoot","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"10.1007\/s13311-023-01446-5_bib23","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-023-01446-5_bib24","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200021","article-title":"Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity","author":"Simpson-Yap","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib25","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001157","article-title":"Influence of previous disease-modifying drug exposure on T-lymphocyte dynamic in patients with multiple sclerosis treated with ocrelizumab","author":"Landi","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","author":"Ellwardt","year":"2018","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-022-11197-6","article-title":"Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression","author":"Dorcet","year":"2022","journal-title":"J Neurol"},{"issue":"9","key":"10.1007\/s13311-023-01446-5_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"\u2018No evident disease activity': The use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-023-01446-5_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge","author":"Gasperini","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-023-01446-5_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp-2019-322348","article-title":"Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis","volume":"91","author":"Prosperini","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-023-01446-5_bib31","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01446-5_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-018-8899-3","article-title":"Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study","author":"Alcal\u00e1","year":"2018","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1352458518772748","article-title":"Efficacy of rituximab in refractory RRMS","author":"Durozard","year":"2019","journal-title":"Mult Scler J"},{"issue":"1","key":"10.1007\/s13311-023-01446-5_bib34","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Havrdov\u00e1","year":"2018","journal-title":"Mult Scler J - Exp Transl Clin"},{"issue":"5","key":"10.1007\/s13311-023-01446-5_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/13524585211035740","article-title":"Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial","volume":"28","author":"Weinstock-Guttman","year":"2022","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"4","key":"10.1007\/s13311-023-01446-5_bib36","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","article-title":"Predictors of ocrelizumab effectiveness in patients with multiple sclerosis","volume":"18","author":"Cellerino","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-023-01446-5_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20\u2013mediated depletion in multiple sclerosis","author":"Nissimov","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1007\/s13311-023-01446-5_bib38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"10.1007\/s13311-023-01446-5_bib39","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1007\/s13311-023-01446-5_bib40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult Scler J"},{"issue":"638","key":"10.1007\/s13311-023-01446-5_bib41","doi-asserted-by":"crossref","first-page":"eabi4632","DOI":"10.1126\/scitranslmed.abi4632","article-title":"Proinflammatory CD20 + T cells contribute to CNS-directed autoimmunity","volume":"14","author":"Ochs","year":"2022","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1007\/s13311-023-01446-5_bib42","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ana.26216","article-title":"Proinflammatory CD20+ T cells are differentially affected by multiple sclerosis therapeutics","volume":"90","author":"Quendt","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib43","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","author":"Perriguey","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"9","key":"10.1007\/s13311-023-01446-5_bib44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-023-01446-5_bib45","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-023-01446-5_bib46","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","author":"Kim","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-023-01446-5_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1007\/s13311-023-01446-5_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-023-01446-5_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1007\/s13311-023-01446-5_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1352458520937282","article-title":"Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity","volume":"27","author":"Longbrake","year":"2021","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"1","key":"10.1007\/s13311-023-01446-5_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ene.12204","article-title":"A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort","volume":"21","author":"Outteryck","year":"2014","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1007\/s13311-023-01446-5_bib52","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult Scler J"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01446-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792302010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792302010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:16:49Z","timestamp":1761808609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792302010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S187874792302010X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01446-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01446-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}